Your browser doesn't support javascript.
Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019-20 Influenza Season-A Retrospective Cohort Analysis.
Levin, Myron J; Divino, Victoria; Shah, Drishti; DeKoven, Mitch; Mould-Quevedo, Joaquin; Pelton, Stephen I; Postma, Maarten J.
  • Levin MJ; Departments of Pediatrics and Medicine, Anschutz Medical Campus, University of Colorado, Aurora, CO 80045, USA.
  • Divino V; Real World Solutions, IQVIA, Falls Church, VA 22042, USA.
  • Shah D; Real World Solutions, IQVIA, Falls Church, VA 22042, USA.
  • DeKoven M; Real World Solutions, IQVIA, Falls Church, VA 22042, USA.
  • Mould-Quevedo J; Global Pricing & Health Economics, Seqirus USA Inc., Summit, NJ 07901, USA.
  • Pelton SI; Department of Pediatrics, Boston University Schools of Medicine, Boston, MA 02118, USA.
  • Postma MJ; Division of Pediatric Infectious Diseases, Maxwell Finland Laboratory, Boston Medical Center, Boston, MA 02118, USA.
Vaccines (Basel) ; 9(10)2021 Oct 08.
Article in English | MEDLINE | ID: covidwho-1481033
ABSTRACT
The burden of influenza is disproportionally higher among older adults. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent (aIIV3) compared to high-dose trivalent influenza vaccine (HD-IIV3e) against influenza and cardio-respiratory disease (CRD)-related hospitalizations/ER visits among adults ≥65 years during the 2019-2020 influenza season. Economic outcomes were also compared. A retrospective cohort analysis was conducted using prescription, professional fee claims, and hospital data. Inverse probability of treatment weighting (IPTW) was used to adjust for confounding. IPTW-adjusted Poisson regression was used to evaluate the adjusted rVE of aIIV3 versus HD-IIV3e. All-cause and influenza-related healthcare resource utilization (HCRU) and costs were examined post-IPTW. Recycled predictions from generalized linear models were used to estimate adjusted costs. Adjusted analysis showed that aIIV3 (n = 798,987) was similarly effective compared to HD-IIV3e (n = 1,655,979) in preventing influenza-related hospitalizations/ER visits (rVE 3.1%; 95% CI -2.8%; 8.6%), hospitalizations due to any cause (-0.7%; 95% CI -1.6%; 0.3%), and any CRD-related hospitalization/ER visit (0.9%; 95% CI 0.01%; 1.7%). Adjusted HCRU and annualized costs were also statistically insignificant between the two cohorts. The adjusted clinical and economic outcomes evaluated in this study were comparable between aIIV3 and HD-IIV3e during the 2019-2020 influenza season.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Year: 2021 Document Type: Article Affiliation country: Vaccines9101146

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Language: English Year: 2021 Document Type: Article Affiliation country: Vaccines9101146